Compass Associates
Multi-award-winning recruitment consultancy dedicated to the independent Health, Social Care and Children's Services sectors.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
GlaxoSmithKline’s once-daily PARP inhibitor Zejula (niraparib) has been approved by the European Commission for first-line monotherapy maintenance treatment for adults with advanced ovarian cancer.